# Humacyte, Inc.: financial statements, quarterly

HUMA · Nasdaq · CIK 1818382 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/huma.md) · [Financials](/companies/huma/financials.md) · [Filings](/companies/huma/filings.md) · [Insiders](/companies/huma/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/huma/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0001818382-25-000076.md) | [0.0](/filings/0001818382-25-000125.md) | [0.0](/filings/0001818382-25-000132.md) | [0.0 d](/filings/0001818382-26-000004.md) | [0.5](/filings/0001193125-26-221755.md) | [0.3](/filings/0001193125-26-347022.md) | [0.8](/filings/0001818382-25-000132.md) | [0.5 d](/filings/0001818382-26-000004.md) | [0.5](/filings/0001193125-26-221755.md) | [0.4](/filings/0001193125-26-347022.md) |
| Cost of revenue | $m | not reported | not reported | [0.0](/filings/0001818382-25-000076.md) | [0.0](/filings/0001818382-25-000125.md) | [0.0](/filings/0001818382-25-000132.md) | [0.0 d](/filings/0001818382-26-000004.md) | [0.1](/filings/0001193125-26-221755.md) | [0.2](/filings/0001193125-26-347022.md) | [0.3](/filings/0001818382-25-000132.md) | [9.1 d](/filings/0001818382-26-000004.md) | [2.0](/filings/0001193125-26-221755.md) | [1.2](/filings/0001193125-26-347022.md) |
| Research and development | $m | [18.6](/filings/0001818382-24-000199.md) | [20.2 d](/filings/0001818382-25-000034.md) | [21.3](/filings/0001818382-25-000076.md) | [23.8](/filings/0001818382-25-000125.md) | [22.9](/filings/0001818382-25-000132.md) | [20.7 d](/filings/0001818382-26-000004.md) | [15.4](/filings/0001193125-26-221755.md) | [22.0](/filings/0001193125-26-347022.md) | [17.3](/filings/0001818382-25-000132.md) | [14.6 d](/filings/0001818382-26-000004.md) | [19.5](/filings/0001193125-26-221755.md) | [18.1](/filings/0001193125-26-347022.md) |
| Selling, general and administrative | $m | not reported | not reported | [5.3](/filings/0001818382-25-000076.md) | [5.7](/filings/0001818382-25-000125.md) | [7.3](/filings/0001818382-25-000132.md) | not reported | [8.1](/filings/0001818382-25-000076.md) | [7.8](/filings/0001818382-25-000125.md) | [7.6](/filings/0001818382-25-000132.md) | not reported | not reported | not reported |
| Operating income | $m | [(24.6)](/filings/0001818382-24-000199.md) | [(26.2) d](/filings/0001818382-25-000034.md) | [(26.6)](/filings/0001818382-25-000076.md) | [(29.5)](/filings/0001818382-25-000125.md) | [(30.2)](/filings/0001818382-25-000132.md) | [(28.1) d](/filings/0001818382-26-000004.md) | [(23.2)](/filings/0001193125-26-221755.md) | [(29.7)](/filings/0001193125-26-347022.md) | [(24.4)](/filings/0001818382-25-000132.md) | [(30.8) d](/filings/0001818382-26-000004.md) | [(28.9)](/filings/0001193125-26-221755.md) | [(27.0)](/filings/0001193125-26-347022.md) |
| Interest expense | $m | [1.5](/filings/0001818382-23-000162.md) | [1.7 d](/filings/0001818382-24-000040.md) | [1.8](/filings/0001818382-24-000056.md) | [2.5](/filings/0001818382-25-000125.md) | [2.4](/filings/0001818382-25-000132.md) | [2.5 d](/filings/0001818382-26-000004.md) | [3.0](/filings/0001193125-26-221755.md) | [2.5](/filings/0001193125-26-347022.md) | [2.6](/filings/0001818382-25-000132.md) | [3.1 d](/filings/0001818382-26-000004.md) | [2.3](/filings/0001193125-26-221755.md) | [2.3](/filings/0001193125-26-347022.md) |
| Income tax | $m | [0.0](/filings/0001818382-24-000199.md) | [0.0 d](/filings/0001818382-25-000034.md) | [0.0](/filings/0001818382-25-000076.md) | [0.0](/filings/0001818382-25-000125.md) | [0.0](/filings/0001818382-25-000132.md) | [0.0 d](/filings/0001818382-26-000004.md) | [0.0](/filings/0001193125-26-221755.md) | [0.0](/filings/0001193125-26-347022.md) | [0.0](/filings/0001818382-25-000132.md) | [0.0 d](/filings/0001818382-26-000004.md) | [0.0](/filings/0001193125-26-221755.md) | [0.0](/filings/0001193125-26-347022.md) |
| Net income | $m | [(26.0)](/filings/0001818382-24-000199.md) | [(25.1) d](/filings/0001818382-25-000034.md) | [(31.9)](/filings/0001818382-25-000132.md) | [(56.7)](/filings/0001818382-25-000132.md) | [(39.2)](/filings/0001818382-25-000132.md) | [(20.9) d](/filings/0001818382-26-000004.md) | [39.1](/filings/0001193125-26-347022.md) | [(37.7)](/filings/0001193125-26-347022.md) | [(17.5)](/filings/0001818382-25-000132.md) | [(24.8) d](/filings/0001818382-26-000004.md) | [(17.6)](/filings/0001193125-26-347022.md) | [(36.8)](/filings/0001193125-26-347022.md) |
| Diluted EPS | $ per share | [(0.25)](/filings/0001818382-24-000199.md) | not reported | [(0.29)](/filings/0001818382-25-000076.md) | [(0.48)](/filings/0001818382-25-000125.md) | [(0.33)](/filings/0001818382-25-000132.md) | not reported | [0.28](/filings/0001193125-26-221755.md) | [(0.24)](/filings/0001193125-26-347022.md) | [(0.11)](/filings/0001818382-25-000132.md) | not reported | [(0.09)](/filings/0001193125-26-221755.md) | [(0.16)](/filings/0001193125-26-347022.md) |
| Basic EPS | $ per share | [(0.25)](/filings/0001818382-24-000199.md) | not reported | [(0.29)](/filings/0001818382-25-000076.md) | [(0.48)](/filings/0001818382-25-000125.md) | [(0.33)](/filings/0001818382-25-000132.md) | not reported | [0.28](/filings/0001193125-26-221755.md) | [(0.24)](/filings/0001193125-26-347022.md) | [(0.11)](/filings/0001818382-25-000132.md) | not reported | [(0.09)](/filings/0001193125-26-221755.md) | [(0.16)](/filings/0001193125-26-347022.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [100.0](/filings/0001818382-23-000162.md) | [80.4](/filings/0001818382-25-000034.md) | [116](/filings/0001818382-24-000056.md) | [93.6](/filings/0001818382-24-000156.md) | [20.6](/filings/0001818382-24-000199.md) | [44.9](/filings/0001818382-26-000004.md) | [62.8](/filings/0001818382-25-000076.md) | [38.0](/filings/0001818382-25-000125.md) | [19.5](/filings/0001818382-25-000132.md) | [50.5](/filings/0001193125-26-347022.md) | [48.5](/filings/0001193125-26-221755.md) | [79.9](/filings/0001193125-26-347022.md) |
| Current assets | $m | [103](/filings/0001818382-23-000162.md) | [83.3](/filings/0001818382-25-000034.md) | [118](/filings/0001818382-24-000056.md) | [96.1](/filings/0001818382-24-000156.md) | [23.0](/filings/0001818382-24-000199.md) | [47.9](/filings/0001818382-26-000004.md) | [73.7](/filings/0001818382-25-000076.md) | [51.7](/filings/0001818382-25-000125.md) | [41.4](/filings/0001818382-25-000132.md) | [67.8](/filings/0001193125-26-347022.md) | [63.6](/filings/0001193125-26-221755.md) | [92.8](/filings/0001193125-26-347022.md) |
| Total assets | $m | [149](/filings/0001818382-23-000162.md) | [128](/filings/0001818382-25-000034.md) | [161](/filings/0001818382-24-000056.md) | [138](/filings/0001818382-24-000156.md) | [115](/filings/0001818382-24-000199.md) | [138](/filings/0001818382-26-000004.md) | [163](/filings/0001818382-25-000076.md) | [139](/filings/0001818382-25-000125.md) | [91.5](/filings/0001818382-25-000132.md) | [116](/filings/0001193125-26-347022.md) | [111](/filings/0001193125-26-221755.md) | [138](/filings/0001193125-26-347022.md) |
| Current liabilities | $m | [15.1](/filings/0001818382-23-000162.md) | [18.4](/filings/0001818382-25-000034.md) | [14.1](/filings/0001818382-24-000056.md) | [17.8](/filings/0001818382-24-000156.md) | [20.9](/filings/0001818382-24-000199.md) | [20.0](/filings/0001818382-26-000004.md) | [20.0](/filings/0001818382-25-000076.md) | [21.1](/filings/0001818382-25-000125.md) | [25.6](/filings/0001818382-25-000132.md) | [18.4](/filings/0001193125-26-347022.md) | [16.2](/filings/0001193125-26-221755.md) | [14.9](/filings/0001193125-26-347022.md) |
| Total liabilities | $m | [112](/filings/0001818382-23-000162.md) | [115](/filings/0001818382-25-000034.md) | [135](/filings/0001818382-24-000056.md) | [167](/filings/0001818382-24-000156.md) | [178](/filings/0001818382-24-000199.md) | [191](/filings/0001818382-26-000004.md) | [127](/filings/0001818382-25-000076.md) | [135](/filings/0001818382-25-000125.md) | [96.3](/filings/0001818382-25-000132.md) | [113](/filings/0001193125-26-347022.md) | [98.9](/filings/0001193125-26-221755.md) | [107](/filings/0001193125-26-347022.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001818382-26-000004.md) | not reported | not reported | not reported | [35.4](/filings/0001193125-26-347022.md) | [35.9](/filings/0001193125-26-221755.md) | [36.3](/filings/0001193125-26-347022.md) |
| Shareholders' equity | $m | [37.0](/filings/0001818382-24-000199.md) | [13.5](/filings/0001818382-26-000004.md) | [26.2](/filings/0001818382-25-000132.md) | [(28.3)](/filings/0001818382-25-000132.md) | [(63.7)](/filings/0001818382-25-000132.md) | [(52.7)](/filings/0001193125-26-347022.md) | [36.0](/filings/0001193125-26-347022.md) | [4.1](/filings/0001193125-26-347022.md) | [(4.8)](/filings/0001818382-25-000132.md) | [3.1](/filings/0001193125-26-347022.md) | [11.6](/filings/0001193125-26-347022.md) | [31.3](/filings/0001193125-26-347022.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.0) d](/filings/0001818382-24-000199.md) | [(19.1) d](/filings/0001818382-25-000034.md) | [(27.3)](/filings/0001818382-25-000076.md) | [(21.3) d](/filings/0001818382-25-000125.md) | [(22.9) d](/filings/0001818382-25-000132.md) | [(26.6) d](/filings/0001818382-26-000004.md) | [(28.6)](/filings/0001193125-26-221755.md) | [(26.4) d](/filings/0001193125-26-347022.md) | [(23.9) d](/filings/0001818382-25-000132.md) | [(26.1) d](/filings/0001818382-26-000004.md) | [(25.1)](/filings/0001193125-26-221755.md) | [(22.1) d](/filings/0001193125-26-347022.md) |
| Capital expenditure | $m | [0.5 d](/filings/0001818382-24-000199.md) | [0.2 d](/filings/0001818382-25-000034.md) | [0.4](/filings/0001818382-25-000076.md) | [0.2 d](/filings/0001818382-25-000125.md) | [0.9 d](/filings/0001818382-25-000132.md) | [0.1 d](/filings/0001818382-26-000004.md) | [0.2](/filings/0001193125-26-221755.md) | [0.6 d](/filings/0001193125-26-347022.md) | [0.0 d](/filings/0001818382-25-000132.md) | [0.0 d](/filings/0001818382-26-000004.md) | [0.2](/filings/0001193125-26-221755.md) | [0.1 d](/filings/0001193125-26-347022.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [103](/filings/0001818382-23-000162.md) | [103](/filings/0001818382-24-000056.md) | [103](/filings/0001818382-24-000156.md) | [103](/filings/0001818382-24-000199.md) | [108](/filings/0001818382-25-000076.md) | [119](/filings/0001818382-25-000125.md) | [119](/filings/0001818382-25-000132.md) | [132](/filings/0001193125-26-221755.md) | [155](/filings/0001193125-26-347022.md) | [158](/filings/0001818382-25-000132.md) | [198](/filings/0001193125-26-221755.md) | [234](/filings/0001193125-26-347022.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 277,798,105 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-347022.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.